The impact of SUMO-modification spans across multiple neurodegenerative diseases, where causal disease proteins can be SUMO modified, including huntingtin (HD),33 amyloid precursor protein (Alzheimer’s disease34), alpha-synuclein (Parkinson’s disease35), androgen receptor (SBMA),36 ataxin-7 (spinocerebellar ataxia 7, SCA737) and ataxin-1 (SCA-138). This evidence concerns the gene AR and spinocerebellar ataxia 7.